저분자 혁신 API CDMO 시장 규모, 점유율, 동향 분석 보고서 : 스테이지 유형별, 고객 유형별, 치료 영역별, 지역별, 부문별 예측(2025-2030년)

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type (Pharmaceutical, Biotechnology), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

저분자 혁신 API CDMO 시장의 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계의 저분자 혁신 API CDMO 시장 규모는 2030년까지 471억 4,000만 달러에 달할것으로 예측되며, 2025-2030년의 CAGR은 6.38%를 나타낼 것으로 예측됩니다.

제약 회사들의 아웃소싱 증가 추세, 저분자 의약품에 대한 수요 증가, 임상시험 건수 급증 등이 시장에 긍정적인 영향을 미칠 것으로 예상됩니다. 제약 부문에서 CDMO의 활용도가 높아지는 이유는 여러 가지가 있지만 비용 효율성이 가장 큰 요인으로 꼽힙니다. 아웃소싱은 제약 회사가 값비싼 인프라 및 장비 투자의 필요성을 회피하여 비용을 절감할 수 있는 효율적인 전략으로 부상하고 있습니다

게다가 효율성 향상은 제약 아웃소싱의 또 다른 중요한 동인으로 작용합니다. 신약을 신속하게 시장에 출시해야 한다는 제약사의 압박이 가중되면서 아웃소싱은 신약 개발 프로세스를 가속화하는 솔루션으로 부상하고 있습니다. CDMO는 전문성, 경험, 첨단 장비를 활용하여 고품질 의약품을 신속하고 효율적으로 생산함으로써 제약사가 개발 일정을 준수할 수 있도록 지원합니다. 또한, 새로운 치료법 및 희귀 의약품의 유입이 증가하고 승인된 제품의 수익률이 높아짐에 따라 여러 제약사가 첨단 인프라와 전문성을 갖춘 CDMO를 선호하고 있습니다. 또한, CDMO의 지속적인 기술 발전은 의료 산업에서 혁신, 효율성 및 규제 준수에 대한 증가하는 수요를 충족하기 위해 혁신적인 저분자 API를 제공합니다.

기업이 첨단 기술을 도입하면 의약품 개발, 제조 공정 및 생산성이 향상됩니다. 2023년 8월 아스텍스는 암 치료를 위한 종양 억제 단백질 저분자 후보를 분류하기 위해 MSD와 연구 협력 및 라이선스 계약을 체결했다고 발표했습니다.

저분자 혁신 API CDMO 시장 보고서 하이라이트

• 임상 단계 유형 부문은 저분자 혁신 API CDMO 산업을 주도했으며 2024년 전 세계 매출의 54.56%를 차지했습니다.
• 제약 부문은 2024년 시장을 지배하여 91.07%의 매출 점유율을 차지했습니다.
• 2024년 저분자 혁신 API CDMO 시장은 종양학 부문이 지배적이며 예측 기간 중 CAGR은 6.80%로 가장 빠르게 성장할 전망입니다.
• 북미의 저분자 혁신 API CDMO 시장은 예측 기간 중 CAGR 5.91%로 성장할 전망입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 저분자 혁신 API CDMO 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련 및 하위 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술
  • 저분자 혁신 API CDMO 시장에 AI 통합
• 단계별 및 지역별 총 임상시험 건수(2021-2024년)
  • 단계별 총 임상시험 건수(2021-2024년)
  • 지역별 임상 검사 총수(2021-2024년)
• 가격 모델 분석
• 시장 분석 도구
  • 포터의 5가지 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 저분자 혁신 API CDMO 시장 : 스테이지 유형별, 추정 및 동향 분석

• 저분자 혁신 API CDMO 시장, 스테이지 유형별 : 부문 대시보드
• 저분자 혁신 API CDMO 시장, 스테이지 유형별 : 변동 분석
• 스테이지 유형별(2018-2030년)
• 전임상
• 임상
  • 1단계
  • 2단계
  • 3단계
• 상업용

제5장 저분자 혁신 API CDMO 시장 : 고객 유형별, 추정 및 동향 분석

• 저분자 혁신 API CDMO 시장, 고객 유형별 : 부문 대시보드
• 저분자 혁신 API CDMO 시장, 고객 유형별 : 변동 분석
• 고객 유형별(2018-2030년)
• 제약
  • 소형
  • 중형
  • 대형
• 생명 공학
  • 소형
  • 중형
  • 대형

제6장 저분자 혁신 API CDMO 시장 : 치료 영역별, 추정 및 동향 분석

• 저분자 혁신 API CDMO 시장, 치료 영역별 : 부문 대시보드
• 저분자 혁신 API CDMO 시장, 치료 영역별 : 변동 분석
• 치료 영역별(2018-2030년)
• 심혈관 질환
• 종양학
• 호흡기 질환
• 신경학
• 대사 장애
• 감염증
• 기타

제7장 저분자 혁신 API CDMO 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 태국
  • 대만
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트
  • 이스라엘

제8장 경쟁 구도

• 시장 진출기업의 분류
• 시장 포지셔닝 분석(2024년 히트맵 분석)
• 기업 프로파일
  • Lonza Group Ltd.
  • Novo Holdings(Catalent, Inc.)
  • Thermo Fisher Scientific, Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • Labcorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences(Jubilant Biosys Limited)
  • WuXi AppTec Co., Ltd.

HBR

영문 목차

영문목차

Small Molecule Innovator API CDMO Market Growth & Trends:

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.38% from 2025 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights:

• The clinical stage type segment led the small molecule innovator API CDMO industry and accounted for 54.56% of global revenue in 2024. The preclinical segment is anticipated to grow at a lucrative CAGR over the forecast period.
• The pharmaceutical segment dominated the market in 2024, accounting for a revenue share of 91.07%. Small-molecule drugs have been the backbone of the pharmaceutical industry for nearly a century. The biotechnology segment's expansion is driven by rising demand for biotechnology and enhanced molecular efficiency.
• The oncology segment dominated the small molecule innovator API CDMO market in 2024 and is expected to grow at the fastest CAGR of 6.80% during the forecast period. The infectious diseases market has witnessed dynamic trends and scenarios across various disease segments.
• North America small molecule innovator API CDMO market is expected to grow at a CAGR of 5.91% over the forecast period. Asia Pacific held the largest market share of 41.74% in 2024.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Stage Type
  • 1.2.2. Customer Type
  • 1.2.3. Therapeutic Area
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Small Molecule Drugs
    • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
    • 3.2.1.3. Surge In Number of Clinical Trials
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Economies
• 3.3. Technological Landscape
  • 3.3.1. Integration of AI in Small Molecule Innovator API CDMO Market
    • 3.3.1.1. Current Dynamics and Future Trends
      • 3.3.1.1.1. Drug Discovery and Design
      • 3.3.1.1.2. AI-Assisted Drug API Synthesis
      • 3.3.1.1.3. Process Optimization
      • 3.3.1.1.4. Supply Chain Management
      • 3.3.1.1.5. Clinical Trial Optimization
      • 3.3.1.1.6. Regulatory Compliance
• 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2024)
  • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2024)
  • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2024)
    • 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
    • 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
    • 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
    • 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
    • 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
    • 3.4.2.6. Total Number of Clinical Trials by Therapeutic Area (2021 - 2024)
• 3.5. Pricing Model Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

• 4.1. Small Molecule Innovator API CDMO Market, By Stage Type: Segment Dashboard
• 4.2. Small Molecule Innovator API CDMO Market, By Stage Type: Movement Analysis
• 4.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Stage Type, 2018 - 2030
• 4.4. Preclinical
  • 4.4.1. Preclinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Clinical
  • 4.5.1. Clinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Phase I
    • 4.5.2.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Phase II
    • 4.5.3.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Phase III
    • 4.5.4.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Commercial
  • 4.6.1. Commercial Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

• 5.1. Small Molecule Innovator API CDMO Market, By Customer Type: Segment Dashboard
• 5.2. Small Molecule Innovator API CDMO Market, By Customer Type: Movement Analysis
• 5.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Customer Type, 2018 - 2030
• 5.4. Pharmaceutical
  • 5.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Small
    • 5.4.2.1. Small Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Medium
    • 5.4.3.1. Medium Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Large
    • 5.4.4.1. Large Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Biotechnology
  • 5.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Small
    • 5.5.2.1. Small Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Medium
    • 5.5.3.1. Medium Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. Large
    • 5.5.4.1. Large Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Segment Dashboard
• 6.2. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Movement Analysis
• 6.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
• 6.4. Cardiovascular Diseases
  • 6.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Oncology
  • 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Respiratory Disorders
  • 6.6.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Neurology
  • 6.7.1. Neurology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Metabolic Disorders
  • 6.8.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Infectious Diseases
  • 6.9.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Japan
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.8. Taiwan
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Framework
    • 7.6.8.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.6. Israel
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Market Position Analysis, 2024 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Lonza Group Ltd.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Novo Holdings (Catalent, Inc.)
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Thermo Fisher Scientific, Inc.
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Siegfried Holding AG
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Recipharm AB
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. CordenPharma International
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Samsung Biologics
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Labcorp
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Ajinomoto Bio-Pharma Services
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Piramal Pharma Solutions
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. WuXi AppTec Co., Ltd.
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives

관련자료